Our patient cohort aligned with the expected demographics in epithelial ovarian cancer (largely high-grade serous histology, average age of 65 years, and 17% BRCA1/BRCA2 mutation rate) but was more heavily pretreated than that in the OCEANS trial cohort. This evidence concerns the gene BRCA1 and ovarian carcinoma.